Webinar
/
June 2, 2021

Is mental health truly equitable?

Webinar
/
This is some text inside of a div block.

Join Big Health's conversation with Delta Air Lines at Business Group on Health's 2021 Annual Conference as we explore mental health equity.

‍

Everyone should have access to effective mental health care. But everyone’s experience with poor mental health is unique and deeply impacted by their identities. Long-standing systemic oppression and discrimination within the US has made it harder for marginalized groups to access and receive quality care.

Watch the conversation on mental health equity between Jae Kullar, General Manager of Global Health and Wellbeing at Delta Air Lines, Dr. Juliette McClendon, Director of Medical Affairs at Big Health, and Peter Hames, CEO and Co-founder of Big Health. They discuss disparities in care, the importance of cultural competency, and how employers can help employees gain a better understanding of mental health so that they feel empowered to seek help.

‍

Copy Link

Watch the replay

Here’s our latest

Tackling Reliance on Z-Drugs: providing digital treatments for insomnia

Dr. Dimitri Gavriloff, Clinical Psychologist and Sleep Medicine Specialist, discusses how to tackle the over prescription of Z-drugs, and the digital treatments available for insomnia and sleep problems. Dr. Gavriloff sheds light on the following topics: The core role of sleep for health and function The Three P’s model of insomnia Sleep hygiene Digital CBT...

Webinar
Both Sides of the Coin: Communicating the Impact of Mental Health Equity & ROI

With nearly half of adult Americans experiencing a clinical mental health issue over the past year, it’s clear we need innovative and effective mental health resources to reach people in need. But providing mental health solutions goes far beyond just checking a box, it is paramount to communicate the importance of providing proven mental health...

Webinar
The state of women in the workplace hangs in the balance

Women face an array of unique stressors — many of which have been compounded by the COVID-19 pandemic. This reality has led to women experiencing higher rates of burnout than their male colleagues. And as a result, women are leaving the workforce at record rates. Fortunately, employers have the incredible power to chip away at,...

Webinar

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023